Innovent Biologics, Inc. has announced the publication of results from a Phase 1 clinical study of its anti-CLDN18.2 ADC, IBI343, for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma. The study results, published in Nature Medicine, demonstrate clinical potential and highlight the therapy's recognition in the international academic community. The successful completion of this study has led to the initiation of a multi-regional Phase 3 clinical trial, G-HOPE-001, in 2024, to further assess the safety and efficacy of IBI343. Innovent Biologics is also investigating the potential applications of IBI343 in treating pancreatic cancer and other diseases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN31609) on July 17, 2025, and is solely responsible for the information contained therein.